Publikationen in Zusammenarbeit mit Forschern von Hacettepe University (9)

2024

  1. Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table

    Journal of Clinical Lipidology

2021

  1. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force

    Atherosclerosis

2020

  1. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

    European Heart Journal, Vol. 41, Núm. 1, pp. 111-188

  2. Current perspectives on the use of statins in the treatment of dyslipidaemic patients: Focus on pitavastatin

    Drugs in Context

2018

  1. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

    European Heart Journal, Vol. 39, Núm. 14, pp. 1131-1143

  2. New prospects for PCSK9 inhibition?

    European heart journal

2017

  1. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: Practical guidance for use in patients at very high cardiovascular risk

    European Heart Journal, Vol. 38, Núm. 29, pp. 2245-2255

2016

  1. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia

    European Heart Journal, Supplement, Vol. 18, pp. C2-C12

2015

  1. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy

    Atherosclerosis Supplements, Vol. 19, pp. 1-12